Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 4201

Next Previous
Drug Profile

INO 4201

Alternative Names: INO-4201

Latest Information Update: 07 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; University Hospitals of Geneva
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 07 Aug 2025 INO 4201 is still in phase I development for Ebola virus infection
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in Switzerland (Intradermal, Injection)
  • 17 Apr 2023 Immunogenicity data from a phase Ib trial in Ebola virus infection released by Inovio Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top